<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074074</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-06023</org_study_id>
    <secondary_id>EORTC-06023</secondary_id>
    <nct_id>NCT00074074</nct_id>
  </id_info>
  <brief_title>Infliximab in Treating Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>Randomized Phase II Trial With Infliximab (Remicade) in Patients With Myelodysplastic Syndrome and a Relatively Low Risk of Developing Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as infliximab, can locate tumor cells and either kill&#xD;
      them or deliver tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of infliximab in treating&#xD;
      patients who have myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the therapeutic activity of 2 different doses of infliximab on peripheral&#xD;
           blood cell count and peripheral and bone marrow blast cell count in patients with low-&#xD;
           or intermediate-risk myelodysplastic syndromes.&#xD;
&#xD;
        -  Determine the subjective and objective toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Determine the response rates (complete and partial response and hematological&#xD;
           improvement) in patients treated with these regimens.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to cytogenetics (good vs intermediate vs unknown due to failure), overall&#xD;
      International Prognostic Scoring System score (low [0] vs intermediate 1 [0.5-1.0] vs&#xD;
      intermediate 2 [1.5-2.0]), and participating center. Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive infliximab IV on days 1, 15, 43, 71, 99, 127, 155, and 183 in&#xD;
           the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive a higher dose of infliximab as in arm I. Patients achieving&#xD;
           response (complete or partial response or hematological improvement) continue therapy&#xD;
           beyond day 183 in the absence of disease progression.&#xD;
&#xD;
      Patients are followed at 2 weeks and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients (40 per treatment arm) will be accrued for this&#xD;
      study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best response as measured by Cheson response criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of highest grade toxicity as assessed by CTCAE v3.0 after response</measure>
  </secondary_outcome>
  <enrollment type="Actual">46</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>infliximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed diagnosis (within the past month) of low- or intermediate-risk&#xD;
             myelodysplastic syndromes (MDS) meeting all of the following criteria:&#xD;
&#xD;
               -  No more than 10% bone marrow blasts (corresponding to refractory anemia [RA], RA&#xD;
                  with ringed sideroblasts, or RA with excess blasts)&#xD;
&#xD;
               -  Meets at least 1 of the following hematopoietic criteria:&#xD;
&#xD;
                    -  Hemoglobin no greater than 10 g/dL OR red blood cell transfusion dependent&#xD;
&#xD;
                    -  Neutrophil count no greater than 1,500/mm^3&#xD;
&#xD;
                    -  Platelet count no greater than 100,000/mm^3 OR platelet transfusion&#xD;
                       dependent&#xD;
&#xD;
               -  No poor cytogenetics (complex abnormalities or involvement of chromosome 7)&#xD;
&#xD;
                    -  Patients with unknown cytogenetics may be eligible provided reasonable&#xD;
                       efforts have been made for determining the cytogenetic profile and the&#xD;
                       results are considered a failure (e.g., normal karyotype [NN] with no more&#xD;
                       than 10 metaphases)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No history of documented hepatitis C&#xD;
&#xD;
          -  No documented active hepatitis B&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT less than 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No clinical history or evidence of congestive heart failure&#xD;
&#xD;
          -  No severe cardiac dysfunction&#xD;
&#xD;
          -  LVEF greater than 35%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No prior or concurrent active or latent tuberculosis (TB)&#xD;
&#xD;
               -  No evidence of prior or concurrent active TB (i.e., fibrotic or pleural scarring,&#xD;
                  pulmonary nodules, mediastinal and/or hilar lymphadenopathy, upper lobe volume&#xD;
                  loss, or cavitation) by chest x-ray&#xD;
&#xD;
               -  Negative intradermal tuberculin skin test (i.e., induration less than 5 mm)&#xD;
&#xD;
          -  No severe pulmonary dysfunction&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No prior or concurrent opportunistic infection (e.g., herpes zoster, cytomegalovirus,&#xD;
             Pneumocystic carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB)&#xD;
             within the past 6 months&#xD;
&#xD;
          -  No concurrent severe (CTC grade III or IV) active, chronic, or recurrent infections&#xD;
&#xD;
          -  No recent history of allergies&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after study&#xD;
             participation&#xD;
&#xD;
          -  No prior clinically significant adverse event to murine or chimeric proteins or&#xD;
             human/murine recombinant products&#xD;
&#xD;
          -  No recent contact with an individual with active TB&#xD;
&#xD;
          -  No poor medical risk due to other systemic disease&#xD;
&#xD;
          -  No multiple sclerosis or other demyelinating disorder&#xD;
&#xD;
          -  No peripheral neuropathy greater than CTC grade 1&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated carcinoma in&#xD;
             situ of the cervix or nonmelanoma skin cancer&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior infliximab or other monoclonal antibodies&#xD;
&#xD;
          -  At least 6 weeks since prior hematopoietic growth factors for MDS&#xD;
&#xD;
          -  At least 3 months since prior therapy targeted at reducing tumor necrosis factor (TNF)&#xD;
             alpha (e.g., pentoxifylline, thalidomide, or etanercept)&#xD;
&#xD;
          -  No concurrent epoetin alfa, filgrastim (G-CSF), or sargramostim (GM-CSF)&#xD;
&#xD;
          -  No other concurrent drugs targeted at reducing TNF alpha (e.g., pentoxifylline,&#xD;
             thalidomide, or etanercept)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior solid organ transplantation&#xD;
&#xD;
               -  Corneal transplantation more than 3 months ago allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior randomization to this clinical trial&#xD;
&#xD;
          -  At least 6 weeks since prior treatment for MDS (except supportive care)&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent therapeutic-dose nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
               -  Concurrent sporadic (no more than 3 tablets/week) over-the-counter NSAIDs allowed&#xD;
&#xD;
          -  Concurrent cardioprotective doses (80 mg/day or equivalent) of aspirin allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heinz Zwierzina, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University Innsbruck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Hartziekenhuis - Roeselaere.</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Peltzer-La Tourelle</name>
      <address>
        <city>Verviers</city>
        <zip>B-4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital - Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Transfusion</name>
      <address>
        <city>Prague</city>
        <zip>128 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruprecht - Karls - Universitaet Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest German Cancer Center at Eberhard-Karls-University</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Salvatore</name>
      <address>
        <city>Pesaro</city>
        <zip>I-61100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Bronovo</name>
      <address>
        <city>Den Haag</city>
        <zip>2597AX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum St. Radboud - Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>NL-6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Baron F, Suciu S, Amadori S, Muus P, Zwierzina H, Denzlinger C, Delforge M, Thyss A, Selleslag D, Indrak K, Ossenkoppele G, de Witte T. Value of infliximab (RemicadeÂ®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica. 2012 Apr;97(4):529-33. doi: 10.3324/haematol.2011.044347. Epub 2011 Nov 18.</citation>
    <PMID>22102701</PMID>
  </results_reference>
  <results_reference>
    <citation>Baila L, Suciu S, Muus P, et al.: Assessment of two doses of infliximab in patients with low/intermediate risk IPSS myelodysplastic syndrome (MDS): an EORTC leukemia group (LG) randomized phase II trial (06023). [Abstract] Blood 110 (11): A-1456, 2007.</citation>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

